The SAFE score shows the greatest net clinical benefit in predicting 10-year cirrhosis risk among patients with noncirrhotic steatotic liver disease (SLD).
FIB-4 and APRI scores also demonstrate strong discrimination for cirrhosis, but SAFE outperforms others in net benefit analyses.
Risk scores for hepatocellular carcinoma (HCC) show limited clinical utility for surveillance decisions in noncirrhotic SLD.
Non-invasive fibrosis scoring and machine-learning models are emerging tools supplementing traditional risk scores, aiding early disease stratification.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
